Photo by iamricozamudio from unsplash
Waldenström macroglobulinemia is an indolent, B-cell lymphoma without a known cure. The bone marrow microenvironment and cytokines both play key roles in Waldenström macroglobulinemia (WM) tumor progression. Only one FDA-approved… Click to show full abstract
Waldenström macroglobulinemia is an indolent, B-cell lymphoma without a known cure. The bone marrow microenvironment and cytokines both play key roles in Waldenström macroglobulinemia (WM) tumor progression. Only one FDA-approved drug exists for the treatment of WM, Ibrutinib, but treatment plans involve a variety of drugs and inhibitors. This review explores avenues of tumor progression and targeted drug therapy that have been investigated in WM and related B-cell lymphomas.
Keywords:
waldenstr macroglobulinemia;
progression;
macroglobulinemia mechanisms;
mechanisms disease;
disease progression
Journal Title: International Journal of Molecular Sciences
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: International Journal of Molecular Sciences
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!